***Background.*** Increasing multidrug resistance in gram-negative bacilli (GNB) infections poses a serious threat to public health. Few studies have analyzed co-resistance rates in detail, defined as an antimicrobial susceptibility profile in a subset resistant to one specific antibiotic. The epidemiologic and clinical utility of determining co-resistance rates are analyzed and discussed.

***Methods.*** A 10-year retrospective study from 2001-2011 of bloodstream infections with GNB were analyzed from three hospitals in Greater Vancouver, BC, Canada. Descriptive statistics were calculated for antimicrobial resistance and co-resistance. Statistical analysis further described temporal trends of antimicrobial resistance, correlations of resistance between combinations of antimicrobials, and temporal trends in co-resistance patterns.

***Results.*** The total number of unique blood stream isolates of GNB was 3280. Increasing resistance to individual antimicrobials was observed for *E. coli*, *K. pneumoniae*, *K. oxytoca*, *E. cloacae*, and *P. aeruginosa*. Ciprofloxacin resistance in *E. coli* peaked in 2006 at 40% and subsequently stabilized at 29% in 2011, corresponding to decreasing ciprofloxacin usage after 2007 as assessed by daily defined dose utilization data. High co-resistance rates were observed for ceftriaxone-resistant *E. coli* with ciprofloxacin (73%), ceftriaxone-resistant *K. pneumoniae* with trimethoprim-sulfamethoxazole (83%), ciprofloxacin-resistant *E. cloacae* with ticarcillin-clavulanate (91%), and piperacillin-tazobactam-resistant *P. aeruginosa* with ceftazidime (83%).

***Conclusion.*** Increasing antimicrobial resistance was demonstrated over the study period, and may partially be associated with antimicrobial consumption. The study of co-resistance rates in multidrug resistant GNB provides insight into the epidemiology of resistance pattern development, and can be used as a clinical tool to aid prescribing empiric antimicrobial therapy.
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